The therapeutic community is demonstrating considerable attention in Asenlix, a relatively developed medication designed to treat the impact of sadness. Unlike established antidepressants that primarily target on serotonin, Asenlix offers a distinct mechanism of action, seemingly impacting various neurotransmitter systems involved in emotional regu